Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo

Cancer Letters(2022)10.1016/j.canlet.2022.215613Source: DataRank Database

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo is a research paper published in Cancer Letters (2022). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.68)OA: hybridTopics (28)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Yinsong Zhu ORCID,Christine Brotherton‐Pleiss,Wen‐Zhen Fu ORCID,Nagendra Verma ORCID,Jasmine Chen

Live enrichment

PubMed:35276290 PMC:PMC9867837 OpenAlex:https://openalex.org/W4220876316

National Institutes of Health

Grant: S10 OD010669

National Cancer Institute

Grant: CA208851

National Cancer Institute

Grant: 19X122Q

NCI NIH HHS

Grant: R01 CA258204

NCI NIH HHS

Grant: R01 CA270324

NCATS NIH HHS

Grant: UL1 TR001881

NCI NIH HHS

Grant: P30 CA030199

NCI NIH HHS

Grant: R01 CA208851

FWCI

1.68

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.canlet.2022.215613

publisherhttps://doi.org/10.1016/j.canlet.2022.215613

publisherhttps://api.elsevier.com/content/article/PII:S030438352200088X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S030438352200088X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35276290

Fields of Study

Synthesis and Catalytic ReactionsSynthesis of β-Lactam CompoundsSynthesis and biological activity

MeSH Terms

AnimalsAzetidinesHumansPhosphorylationSignal TransductionApoptosisCell Line, TumorSTAT3 Transcription FactorMiceTriple Negative Breast Neoplasms

Keywords

In vivoAzetidinePharmacologyCell growthCancer researchChemistryIn vitroBiologyBiochemistryStereochemistrycovalent modificationSignal Transducer And Activator Of TranscriptionTumor Growth InhibitionSmall-molecule InhibitorsAntitumor Cell Effects

Sustainable Development Goals

SDG 0: Good health and well-being

Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo

FAIR Checklist

Authors (22)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)